Find a Clinical Trial

Showing 161 - 170 of 196 Trials

  • A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or RefractoryMultiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational

    Principal Investigator:

    Divaya Bhutani, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06121843

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test whether BMS-986393 in combination with other anti- cancer drugs is safe and effective at treating people with multiple myeloma (MM) that has come back after previous treatment (relapsed) or is not responding to current treatment (refractory). The researchers think that the combinations of alnuctamab, mezigdomide, or iberdomide with BMS-986393 in people with relapsed/refractory MM may improve their disease or keep their disease under control. This is an open-label, multicenter study that will recruit potential participants in the United States (USA) and...

  • An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis

    Principal Investigator:

    Rajshekhar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06158854

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the abnormal proteins that cause amyloidosis. The study drug ABBV-383, is not approved by the U.S Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years or older - Must consent to fresh pretreatment bone marrow...

  • A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

    Principal Investigator:

    Lanyi Nora Chen, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04389632

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to study SGN-B6A alone, with pembrolizumab, or with pembrolizumab and one of the chemotherapy drugs (cisplatin or carboplatin). The sponsor wants to find out what its side effects are and if it works for specific types of cancer. It is not yet know if SGN-B6A alone or with other drugs is better or worse than other treatments. This clinical trial uses an experimental drug. This means the Food and Drug Administration (FDA) hasn’t approved it for sale in the United States. This drug is called SGN-B6A. This clinical trial also uses pembrolizumab. The brand name...

  • A Phase 1a/1b Study of LY4052031, an Antibody-Drug ConjugateTargeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06465069

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully known yet. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Life expectancy must be more than 12 weeks - Must not have uncontrolled diabetes

  • A MULTICENTER, OPEN-LABEL PHASE 1/1B DOSE-FINDING, SAFETY, AND PHARMACOKINETIC STUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYL AURISTATIN E(MMAE) ANTIBODY DRUG CONJUGATE, IN ADVANCED REFRACTORY SOLID TUMORS

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06014658

    Population:

    Adult

    Phase:

    I
    The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...

  • A Phase 1 Open-Label Study of PF-07985045 as a Single-Agent and in Combination with Other Anti-Cancer Agents in Participants with Advanced Solid Tumors

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06704724

    Population:

    Adult

    Phase:

    I
    The purposes of this research study are (1) to learn about the safety and the effects of study drug, PF-07985045 on your specific cancer and on your body, with or without combination drugs and (2) to find the best dose for treating your specific type of cancer, as well as treating other types of cancers. This study is divided in two parts: Part 1 and Part 2. Part 1 testing and results applies to the study drug alone, called monotherapy. The goal of Part 1 is to determine the maximum tolerated dose (highest dose that is safe and tolerable in study participants, called MTDM and the recommended...

  • A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial)

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06625775

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find the best dose and effects of BBO-10203 when used alone or in combination with Trastuzumab in HER2-positive advanced breast cancer (aBC) or HR- positive, HER2-negative aBC or advanced non-small cell lung cancer (aNSCLC) with a KRAS (Kirsten rat sarcoma) mutation or advanced colorectal cancer (aCRC) with a KRAS mutation.BBO-10203 has not been approved by the Food and Drug Administration (FDA). Trastuzumab is FDA approved but not in combination with BBO-10203. This is a first in human study. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older...

  • A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab inPatients With Advanced or Metastatic Hepatocellular Carcinoma

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06600321

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of an investigational drug called ALN-BCAT, and find out what effects, if any, ALN-BCAT has on people with your type of liver cancer. The effects being studied include: • The frequency and severity of side effects (to determine if the drug is safe) • Whether ALN-BCAT may make tumors smaller • How ALN-BCAT may affect the genes and proteins in your cancer cells • How your body processes ALN-BCAT Are you Eligible? (Inclusion Criteria) Age 18 years or older - Patient able to understand and willing and able to comply with...

  • A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD6008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation (TIAN-SHAN1)

    Principal Investigator:

    Catherine Shu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06813365

    Population:

    Adult

    Phase:

    I
    This study is a Phase 1 clinical trial, which means it is the first stage of testing a new drug in humans to evaluate its safety, determine how the body processes it, and identify any potential side effects. The drug being studied, DZD6008, is investigational, meaning it has not been approved by the U.S. Food and Drug Administration (FDA). This study is evaluating the study drug, DZD6008, in patients with advanced non small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. EGFR is a protein that is important in regulating activities in cell proliferation...

  • CHRONIC CONVECTION ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT MALIGNANT GLIOMA

    Principal Investigator:

    Jeffrey N Bruce, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine the safety of directly injecting a chemotherapy drug called Topotecan and a contrast agent called Gadolinium into malignant brain tumors. Currently there is no effective treatment for recurrent malignant brain tumors, which means the brain tumor has returned after the original tumor has been treated. Most systemic chemotherapy drugs have toxic side effects, which make them difficult to use for brain tumors. However, we are doing this study to find out if using an experimental method of directly infusing the drug into the tumor, allows research...

Pages